| 1 |
34473615 | In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity. | 2021 |
3 |
| 2 |
32415468 | Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. | 2020 Jul |
1 |
| 3 |
32529309 | Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect. | 2020 Jun 11 |
1 |
| 4 |
29199506 | Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin. | 2019 Apr |
2 |
| 5 |
31417408 | Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors. | 2019 |
1 |
| 6 |
29223619 | Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver. | 2018 Mar 1 |
1 |
| 7 |
28383355 | Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. | 2017 Jun |
2 |
| 8 |
26693810 | In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. | 2016 Apr |
5 |
| 9 |
26965514 | A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. | 2016 Jun |
1 |
| 10 |
28261657 | Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia. | 2016 |
1 |
| 11 |
26178713 | Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. | 2015 Nov |
1 |
| 12 |
26300393 | Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. | 2015 Oct 15 |
1 |
| 13 |
24739665 | Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile. | 2014 Dec |
5 |
| 14 |
24844604 | Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. | 2014 Jul |
1 |
| 15 |
23028140 | Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. | 2013 Jan |
10 |
| 16 |
23394826 | Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. | 2013 Nov |
2 |
| 17 |
23657159 | Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. | 2013 Sep |
1 |
| 18 |
22014153 | Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. | 2012 Apr |
14 |
| 19 |
21350820 | Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. | 2011 May |
3 |
| 20 |
20054526 | CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. | 2010 Apr |
3 |
| 21 |
20699073 | [Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits]. | 2010 May-Jun |
1 |
| 22 |
20977456 | Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. | 2010 Nov |
3 |
| 23 |
27392989 | [Not Available]. | 2010 May-Jun |
1 |
| 24 |
18188833 | In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. | 2008 Mar |
1 |
| 25 |
18781906 | Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. | 2008 Sep |
1 |
| 26 |
19088049 | Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. | 2008 Dec 15 |
1 |
| 27 |
17180388 | The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. | 2007 May |
3 |
| 28 |
18094422 | Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. | 2007 Dec 15 |
5 |
| 29 |
16890580 | Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. | 2006 Aug |
1 |
| 30 |
16914578 | Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. | 2006 Aug 15 |
2 |
| 31 |
16122278 | Clinical pharmacokinetics of imatinib. | 2005 |
1 |
| 32 |
16286749 | Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. | 2005 |
2 |
| 33 |
14605865 | Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. | 2004 Feb |
2 |
| 34 |
15350151 | Drug interactions with St John's wort : mechanisms and clinical implications. | 2004 |
1 |
| 35 |
15470331 | Effect of St John's wort on imatinib mesylate pharmacokinetics. | 2004 Oct |
1 |
| 36 |
14612892 | Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | 2003 Nov 17 |
4 |
| 37 |
12006504 | Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. | 2002 May |
1 |